{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Myovant+Sciences+GmbH", "query": { "sponsor": "Myovant Sciences GmbH" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 13, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Myovant+Sciences+GmbH&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-12T11:54:40.349Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03412890", "title": "LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Heavy Menstrual Bleeding", "Uterine Fibroid" ], "interventions": [ { "name": "Relugolix", "type": "DRUG" }, { "name": "Estradiol/norethindrone acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Myovant Sciences GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "FEMALE", "summary": "18 Years to 50 Years · Female only" }, "enrollment_count": 477, "start_date": "2017-10-19", "completion_date": "2021-01-13", "has_results": true, "last_update_posted_date": "2024-05-09", "last_synced_at": "2026-10-12T11:54:40.349Z", "location_count": 104, "location_summary": "Andalusia, Alabama • Birmingham, Alabama • Mobile, Alabama + 84 more", "locations": [ { "city": "Andalusia", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03412890" }, { "nct_id": "NCT03049735", "title": "LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Heavy Menstrual Bleeding", "Uterine Fibroid" ], "interventions": [ { "name": "Relugolix", "type": "DRUG" }, { "name": "Estradiol/norethindrone acetate", "type": "DRUG" }, { "name": "Estradiol/norethindrone acetate placebo", "type": "DRUG" }, { "name": "Relugolix placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Myovant Sciences GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "FEMALE", "summary": "18 Years to 50 Years · Female only" }, "enrollment_count": 388, "start_date": "2017-04-26", "completion_date": "2020-08-24", "has_results": true, "last_update_posted_date": "2022-04-19", "last_synced_at": "2026-10-12T11:54:40.349Z", "location_count": 76, "location_summary": "Andalusia, Alabama • Mobile, Alabama • Little Rock, Arkansas + 62 more", "locations": [ { "city": "Andalusia", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Mesa", "state": "California" }, { "city": "Lomita", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03049735" }, { "nct_id": "NCT03654274", "title": "SPIRIT EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Endometriosis-Associated Pain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Endometriosis" ], "interventions": [ { "name": "Relugolix", "type": "DRUG" }, { "name": "Estradiol/norethindrone acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Myovant Sciences GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "51 Years", "sex": "FEMALE", "summary": "18 Years to 51 Years · Female only" }, "enrollment_count": 802, "start_date": "2018-05-22", "completion_date": "2023-01-31", "has_results": true, "last_update_posted_date": "2023-08-08", "last_synced_at": "2026-10-12T11:54:40.349Z", "location_count": 60, "location_summary": "Andalusia, Alabama • Scottsdale, Arizona • Tucson, Arizona + 50 more", "locations": [ { "city": "Andalusia", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Canoga Park", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03654274" }, { "nct_id": "NCT03751124", "title": "Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Uterine Leiomyoma", "Uterine Fibroids" ], "interventions": [ { "name": "Relugolix", "type": "DRUG" }, { "name": "Estradiol/norethindrone acetate", "type": "DRUG" }, { "name": "Placebo for relugolix", "type": "DRUG" }, { "name": "Placebo for E2/NETA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Myovant Sciences GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "51 Years", "sex": "FEMALE", "summary": "18 Years to 51 Years · Female only" }, "enrollment_count": 229, "start_date": "2018-10-16", "completion_date": "2021-10-20", "has_results": true, "last_update_posted_date": "2024-06-25", "last_synced_at": "2026-10-12T11:54:40.349Z", "location_count": 72, "location_summary": "Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 61 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Canoga Park", "state": "California" }, { "city": "Huntington Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03751124" }, { "nct_id": "NCT03085095", "title": "A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Relugolix", "type": "DRUG" }, { "name": "Leuprolide Acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Myovant Sciences GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 1134, "start_date": "2017-04-18", "completion_date": "2021-11-26", "has_results": true, "last_update_posted_date": "2022-01-18", "last_synced_at": "2026-10-12T11:54:40.349Z", "location_count": 27, "location_summary": "Tucson, Arizona • Orange, California • Denver, Colorado + 24 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Pompano Beach", "state": "Florida" }, { "city": "Jeffersonville", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03085095" }, { "nct_id": "NCT04978688", "title": "Study of Relugolix Alone and Relugolix Combined With Hormonal Add-Back Therapy in Healthy Premenopausal Female Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Relugolix", "type": "DRUG" }, { "name": "E2/NETA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Myovant Sciences GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "48 Years", "sex": "FEMALE", "summary": "18 Years to 48 Years · Female only" }, "enrollment_count": 48, "start_date": "2016-06-16", "completion_date": "2016-09-21", "has_results": false, "last_update_posted_date": "2021-07-27", "last_synced_at": "2026-10-12T11:54:40.349Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04978688" }, { "nct_id": "NCT03103087", "title": "LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Heavy Menstrual Bleeding", "Uterine Fibroid" ], "interventions": [ { "name": "Relugolix", "type": "DRUG" }, { "name": "Estradiol/norethindrone acetate", "type": "DRUG" }, { "name": "Relugolix placebo", "type": "DRUG" }, { "name": "Estradiol/norethindrone acetate placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Myovant Sciences GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "FEMALE", "summary": "18 Years to 50 Years · Female only" }, "enrollment_count": 382, "start_date": "2017-06-14", "completion_date": "2020-09-16", "has_results": true, "last_update_posted_date": "2022-04-20", "last_synced_at": "2026-10-12T11:54:40.349Z", "location_count": 89, "location_summary": "Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 78 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Canoga Park", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03103087" }, { "nct_id": "NCT03204318", "title": "SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Endometriosis Related Pain" ], "interventions": [ { "name": "Relugolix", "type": "DRUG" }, { "name": "Estradiol/norethindrone acetate", "type": "DRUG" }, { "name": "Estradiol/norethindrone acetate placebo", "type": "DRUG" }, { "name": "Relugolix placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Myovant Sciences GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "FEMALE", "summary": "18 Years to 50 Years · Female only" }, "enrollment_count": 638, "start_date": "2017-12-07", "completion_date": "2021-04-08", "has_results": false, "last_update_posted_date": "2021-06-28", "last_synced_at": "2026-10-12T11:54:40.349Z", "location_count": 43, "location_summary": "Dothan, Alabama • Mesa, Arizona • Scottsdale, Arizona + 37 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03204318" }, { "nct_id": "NCT05324098", "title": "Leveraging Technology to Achieve Equity for Men With Prostate Cancer on Androgen Deprivation Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "STAND-T platform", "type": "OTHER" }, { "name": "Survey Administration", "type": "OTHER" }, { "name": "Text Messages", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 47, "start_date": "2022-03-08", "completion_date": "2023-07-31", "has_results": false, "last_update_posted_date": "2024-06-10", "last_synced_at": "2026-10-12T11:54:40.349Z", "location_count": 2, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05324098" }, { "nct_id": "NCT04714554", "title": "A Study of the Effects of Erythromycin on the Pharmacokinetics of Relugolix, Estradiol, and Norethindrone in Healthy Postmenopausal Women and on the Pharmacokinetics of Relugolix in Healthy Adult Men", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Relugolix/E2/NETA FDC", "type": "DRUG" }, { "name": "Relugolix", "type": "DRUG" }, { "name": "Erythromycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Myovant Sciences GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 43, "start_date": "2021-01-06", "completion_date": "2021-03-29", "has_results": false, "last_update_posted_date": "2021-09-01", "last_synced_at": "2026-10-12T11:54:40.349Z", "location_count": 1, "location_summary": "Hialeah, Florida", "locations": [ { "city": "Hialeah", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04714554" } ] }